Vida Ventures Marks Fourth Major Portfolio Acquisition in 2025, Capping a Record-Setting Year for Its Science-Led, Discipline-Driven Strategy
Vida Ventures (“Vida”), a next-generation life sciences venture firm, today announced its fourth major Vida portfolio acquisition of 2025, capping an unprecedented year of strategic exits and reinforcing the firm’s disciplined, science-first approach to company building and investing.
Vida Ventures Taps Industry Heavyweights from JP Morgan and MPM BioImpact to Further Power Leadership Team
Vida Ventures (“Vida”), a next-generation life sciences venture firm, today announced the addition of Matt Cohen, MD, MBA, and Brian Goodman, PhD, as Managing Directors. Their appointments mark a strategic evolution that further strengthens the firm’s ability to source, build and scale transformative biomedical companies from inception through crossover and public market investing.
